Nivolumab and DAY101 for Treatment of Craniopharyngioma in Children and Young Adults
Status:
Not yet recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
The current study assesses the tolerability and efficacy of combination therapy with PD-1
(nivolumab) and pan-RAF-kinase (DAY101) inhibition for the treatment of children and young
adults with craniopharyngioma.
Phase:
Phase 2
Details
Lead Sponsor:
Sabine Mueller, MD, PhD
Collaborators:
Bristol-Myers Squibb Day One Biopharmaceuticals, Inc.